Summary
When intramuscular chlorpromazine was given to fourteen patients, those patients who had not been given chlorpromazine before this study showed a rise of the serum transaminases to significantly abnormal levels. In those patients previously exposed to chlorpromazine, the serum transaminases did rise in the same manner, but not to an abnormal or significant degree.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartholomew, L.G., Cain, J.C., Frazier, S.H., Petersen, M.C., Foulk, W.T., Soule, E.H., Fleisher, G.A., Owen, C.A., Jr.: Effect of chlorpromazine on the liver. Gastroenterology34, 1096–1107 (1958)
Greenhouse, S.W., Geiser, S.: Methods in the analysis of profile data. Psychometrika24, 95–112 (1959)
Pryse-Davies, J., Wilkinson, J.H.: Diagnostic value of serum-transaminase activity in hepatic and gastrointestinal diseases. Lancet1958 I, 1249–1253
Shay, H., Siplet, H.: Study of chlorpromazine jaundice, its mechanism and prevention (special reference to serum alkaline phosphatase and glutamic oxalacetic transaminase). Gastroenterology32, 571–591 (1957)
Waitzkin, L.: Hepatic dysfunction due to chlorpromazine hypersensitivity. Ann. Intern. Med.49, 607–619 (1958)
Wroblewski, F., La Due, J.S.: Serum glutamic pyruvic transaminase (SGP-T) in hepatic disease: A preliminary report. Ann. Intern. Med.45, 801–811 (1956)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Evans, L., Hassanyeh, F., Gallacher, J. et al. The effect of intramuscular chlorpromazine on the serum transaminases (SGOT and SGPT). Eur J Clin Pharmacol 10, 289–292 (1976). https://doi.org/10.1007/BF00558342
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558342